logo-loader
Motif Bio PLC

Motif Bio's Graham Lumsden updates on FDA discussions and iclaprim potential

Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim.

Feedback from that meeting is expected in early June.

Motif's acknowledged additional data will likely be required to address the agency’s concern about a risk of liver toxicity, although it will wait to hear what the FDA has to say before deciding the size and scope of any potential study.

Quick facts: Motif Bio PLC

Price: £0.02

Market: AIM
Market Cap: £7.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

2 min read